CN104547514A - Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof - Google Patents

Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof Download PDF

Info

Publication number
CN104547514A
CN104547514A CN201410812739.2A CN201410812739A CN104547514A CN 104547514 A CN104547514 A CN 104547514A CN 201410812739 A CN201410812739 A CN 201410812739A CN 104547514 A CN104547514 A CN 104547514A
Authority
CN
China
Prior art keywords
parts
chinese medicine
medicine composition
radix
lupus erythematosus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410812739.2A
Other languages
Chinese (zh)
Inventor
邓凤桂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Original Assignee
GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd filed Critical GUANGDONG JUZHICHENG TECHNOLOGY Co Ltd
Priority to CN201410812739.2A priority Critical patent/CN104547514A/en
Publication of CN104547514A publication Critical patent/CN104547514A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/19Acanthaceae (Acanthus family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236Ligusticum (licorice-root)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/36Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/37Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/39Convolvulaceae (Morning-glory family), e.g. bindweed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481Astragalus (milkvetch)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537Salvia (sage)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/538Schizonepeta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539Scutellaria (skullcap)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/54Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/804Rehmannia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8968Ophiopogon (Lilyturf)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/51Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50Methods involving additional extraction steps
    • A61K2236/53Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Abstract

The invention belongs to the field of medicine, and relates to a traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof. The invention provides a traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis in order to compensate the defects in the prior art and to relieve the pain of patients suffered from systemic lupus erythematosus. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-12 parts of fructus arctii, 5-8 parts of herba schizonepetae, 6-9 parts of astragalus membranaceus, 3-5 parts of semen cuscutae, 10-12 parts of radix rehmanniae, 10-12 parts of andrographis paniculata, 3-5 parts of szechuan lovage rhizome, 3-5 parts of tripterygium wilfordii, 10-12 parts of gingko leaves, 8-10 parts of cassia twig, 6-9 parts of eclipta alba, 10-12 parts of starwort root, 10-12 parts of barbed skullcap herb, 10-12 parts of radix salviae miltiorrhizae, 12-15 parts of cattail pollen and 9-12 parts of dwarf lilyturf turber. The therapeutic drug can remarkably adjust the activity of T cell subgroups, has the therapeutic effect on vasculitis, is obvious in curative effect, and has wide clinical application prospects.

Description

Systemic lupus erythematosus merges vasculitic Chinese medicine composition and uses thereof
Technical field
The invention belongs to field of medicaments, relate to a kind of systemic lupus erythematosus and merge vasculitic Chinese medicine composition and uses thereof.
Background technology
Systemic lupus erythematosus (sle) (systemiclupuserythematosus; SLE) be a kind of diffusivity, systemic autoimmune diseases, mainly involve mucocutaneous, skeletal muscle, kidney and central nervous system, also may involve multiple organ and the systems such as lung, heart, blood simultaneously, show various clinical symptoms, along with time lapse, systemic lupus erythematosus (sle) is not effected a radical cure and seriously can be caused a lot of complication, and this problem causes the concern of people.It is careful that treatment for systemic lupus erythematosus (sle) needs, and only has radical cure systemic lupus erythematosus (sle) just can avoid complication.Wherein common with the complication of cardiovascular system.The hematological of lupus erythematosus is the most common with vasculitis, with extremity, patient often occurs that large stretch of cicatrix petechia of unknown cause is for main clinical manifestation, if do not find timely and treat and develop as one pleases, the limb end of finger tip, toe point will be caused to occur the serious consequence such as depression and ulcer necrosis.
The systemic lupus erythematosus (sle) cause of disease and pathogeny are still not clear, multiple autoantibody and crucial immunological abnormality can be detected in Serum in Patients with SLE, lymphocyte function exception and cytokine profiles secretion is unbalance plays an important role in the developing of this disease, has CD in research authentication system lupus erythematosus disease human peripheral 3+cD 4+t cell declines, CD 3+cD 8+t rises, and IL-10 level raises, and wherein IL-10 receives much attention in SLE pathogenesis as the representative of Th type cytokines.Interleukin is the polypeptide class of the non-homogeneous adjustment Growth of Cells of a large class, differentiation, mediation signal transmission, and IL-10 is more concerned in systemic lupus erythematosus (sle) research.IL-10 is a pleiotropic cytokines, and have immunostimulation and immunosuppressant dual function, its immunostimulation mainly improves the survival rate of B cell, promotes the secretion of the expression of the propagation of B cell, MHC-class Ⅱ antigens and antibody.There are some researches show that IL-10 can produce Anti-hCG action by stimulating system patients with SLE PBMCs.Research shows that no matter Patients with SLE is in active stage or catabasis, and in its body, IL-l0 level is all the time higher than normal person.
Systemic lupus erythematosus (sle) there is no radical cure way at present, the long-term even life-long therapy of a lot of needs of patients.Doctor trained in Western medicine controls the therapy of systemic lupus erythematosus (sle) many employings hormone, hormone is controlled systemic lupus erythematosus (sle) and is had distinguished curative effect, but hormone has sizable side effect, and use hormones a large amount of is for a long time unfavorable for the physical and mental health of patient, moreover, subtracting of hormone stops very likely causing aggravation.The way of middle treatment systemic lupus erythematosus (sle) many employings Chinese drugs dispensing, though Chinese drugs dispensing controls systemic lupus erythematosus (sle) have distinguished curative effect, but curative effect only rests on relief of symptoms side, be difficult to fundamentally treat systemic lupus erythematosus (sle), middle treatment systemic lupus erythematosus (sle) is a long-term process, just sees curative effect after generally adhering to treating half a year.Therefore, all there is certain limitation in the Therapeutic Method of current systemic lupus erythematosus (sle).Therefore, find a kind of new active drug to carry out systemic lupus erythematosus and merge vasculitis patient and have very important meaning.
Summary of the invention
In order to make up the deficiencies in the prior art, the misery that mitigation system lupus erythematosus and complication vasculitis thereof cause to patient, the invention provides a kind of systemic lupus erythematosus and merge vasculitic Chinese medicine composition, it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
A kind of systemic lupus erythematosus merges vasculitic Chinese medicine composition, and this Chinese medicine composition is made up of the raw material of following weight portion: Fructus Arctii 10-12 part, Herba Schizonepetae 5-8 part, Radix Astragali 6-9 part, Semen Cuscutae 3-5 part, Radix Rehmanniae 10-12 part, Herba Andrographis 10-12 part, Rhizoma Chuanxiong 3-5 part, Radix Tripterygii Wilfordii 3-5 part, Folium Ginkgo 10-12 part, Ramulus Cinnamomi 8-10 part, Herba Ecliptae 6-9 part, Radix Stellariae 10-12 part, Herba Scutellariae Barbatae 10-12 part, Radix Salviae Miltiorrhizae 10-12 part, Pollen Typhae 12-15 part, Radix Ophiopogonis 9-12 part.
In Chinese medicine composition described above, Radix Angelicae Sinensis 5-8 part and Radix Notoginseng 12-15 part can also be contained.This two tastes Chinese medicine can strengthen the above-mentioned Chinese medicine composition of the present invention further and merge vasculitic therapeutic effect to systemic lupus erythematosus (sle).Chinese medicine described above is all got its conventional medicinal part and is used as medicine.
The present invention also asks to protect above-mentioned Chinese medicine composition preparing the purposes in systemic lupus erythematosus merging vasculitis medicine.Test examples 7 of the present invention shows, in the test of t lymphocyte subset cluster analysis, compared with SLE model group, and the CD that Chinese medicine composition of the present invention can make SLE sample mice decline 3+cD 4+t cell rises, and makes the CD of rising 3+cD 8+t cell declines, and corrects the imbalance state of T cell subgroup; In serum IL-10, the test of anti-ds-DNA antibody assay, compared with SLE model group, Chinese medicine composition of the present invention significantly can reduce the rising of SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition, illustrates that medicine of the present invention is remarkable for SLE mice therapeutic effect; In the determination test of microdose urine protein, SLE model group albumin content obviously raises, reflection SLE mouse kidney has damage, the present invention significantly can reduce albuminous content in SLE mice urine, Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference, show that medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.The embodiment of the present invention 8 shows, compare with model group, Chinese medicine composition of the present invention each dosage group basic, normal, high all significantly or pole significantly reduce the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity, reduction amplitude amount effect relationship, wherein high dose there were significant differences ( p<0.05).Chinese medicine composition of the present invention is better than positive control drug Tripterygium Hypoglaucum Hutch Tablet in activating blood circulation to dissipate blood stasis.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into dosage form conventional clinically.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into powder, water preparation, tablet or capsule.
Present invention also offers a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
Chinese medicine composition of the present invention merges in vasculitis at systemic lupus erythematosus, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and improves the quality of life of patient.
2) multi-medicament component is contained in Chinese medicine composition of the present invention, action target spot is numerous, pharmacological evaluation shows it and existing Therapy for Systemic Lupus Erythematosus medicine has significant synergism in treatment, and can significantly reduce systemic lupus erythematosus disease, improve the compliance of patient.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but those skilled in the art should know, described embodiment does not also limit the present invention in any way.
one) example of formulations part
embodiment 1 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Arctii 10 parts, Herba Schizonepetae 5 parts, the Radix Astragali 6 parts, Semen Cuscutae 3 parts, 10 parts, the Radix Rehmanniae, Herba Andrographis 10 parts, Rhizoma Chuanxiong 3 parts, Radix Tripterygii Wilfordii 3 parts, Folium Ginkgo 10 parts, Ramulus Cinnamomi 8 parts, Herba Ecliptae 6 parts, Radix Stellariae 10 parts, Herba Scutellariae Barbatae 10 parts, Radix Salviae Miltiorrhizae 10 parts, Pollen Typhae 12 parts, Radix Ophiopogonis 9 parts
Get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, add according to 4 ~ 9 times of coarse powder gross weight the alcoholic solution that volumetric concentration is 40% ~ 95%, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
embodiment 2 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Arctii 12 parts, Herba Schizonepetae 8 parts, the Radix Astragali 9 parts, Semen Cuscutae 5 parts, 12 parts, the Radix Rehmanniae, Herba Andrographis 12 parts, Rhizoma Chuanxiong 5 parts, Radix Tripterygii Wilfordii 5 parts, Folium Ginkgo 12 parts, Ramulus Cinnamomi 10 parts, Herba Ecliptae 9 parts, Radix Stellariae 12 parts, Herba Scutellariae Barbatae 12 parts, Radix Salviae Miltiorrhizae 12 parts, Pollen Typhae 15 parts, Radix Ophiopogonis 12 parts.
Preparation method is with embodiment 1.
embodiment 3 parts of Chinese medicine compositions of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Arctii 11 parts, Herba Schizonepetae 7 parts, the Radix Astragali 7 parts, Semen Cuscutae 4 parts, 11 parts, the Radix Rehmanniae, Herba Andrographis 11 parts, Rhizoma Chuanxiong 4 parts, Radix Tripterygii Wilfordii 4 parts, Folium Ginkgo 11 parts, Ramulus Cinnamomi 9 parts, Herba Ecliptae 8 parts, Radix Stellariae 11 parts, Herba Scutellariae Barbatae 11 parts, Radix Salviae Miltiorrhizae 11 parts, Pollen Typhae 13 parts, Radix Ophiopogonis 10 parts.
Preparation method is with embodiment 1.
embodiment 4 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Arctii 10 parts, Herba Schizonepetae 5, the Radix Astragali 6 parts, Semen Cuscutae 3 parts, 10 parts, the Radix Rehmanniae, Herba Andrographis 10 parts, Rhizoma Chuanxiong 3 parts, Radix Tripterygii Wilfordii 3 parts, Folium Ginkgo 10 parts, Ramulus Cinnamomi 8 parts, Herba Ecliptae 6 parts, Radix Stellariae 10 parts, Herba Scutellariae Barbatae 10 parts, Radix Salviae Miltiorrhizae 10 parts, Pollen Typhae 12 parts, Radix Ophiopogonis 9, Radix Angelicae Sinensis 5, Radix Notoginseng 13 parts
Preparation method is with embodiment 1.
embodiment 5 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Arctii 12 parts, Herba Schizonepetae 8 parts, the Radix Astragali 9 parts, Semen Cuscutae 5 parts, 12 parts, the Radix Rehmanniae, Herba Andrographis 12 parts, Rhizoma Chuanxiong 5 parts, Radix Tripterygii Wilfordii 5 parts, Folium Ginkgo 12 parts, Ramulus Cinnamomi 10 parts, Herba Ecliptae 9 parts, Radix Stellariae 12 parts, Herba Scutellariae Barbatae 12 parts, Radix Salviae Miltiorrhizae 12 parts, Pollen Typhae 15 parts, Radix Ophiopogonis 12 parts, Radix Angelicae Sinensis 8 parts, Radix Notoginseng 12 parts.
Preparation method is with embodiment 1.
embodiment 6 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: Fructus Arctii 11 parts, Herba Schizonepetae 7 parts, the Radix Astragali 7 parts, Semen Cuscutae 4 parts, 11 parts, the Radix Rehmanniae, Herba Andrographis 11 parts, Rhizoma Chuanxiong 4 parts, Radix Tripterygii Wilfordii 4 parts, Folium Ginkgo 11 parts, Ramulus Cinnamomi 9 parts, Herba Ecliptae 8 parts, Radix Stellariae 11 parts, Herba Scutellariae Barbatae 11 parts, Radix Salviae Miltiorrhizae 11 parts, Pollen Typhae 13 parts, Radix Ophiopogonis 10 parts, Radix Angelicae Sinensis 6 parts, Radix Notoginseng 15 parts.
Preparation method is with embodiment 1.
(2) test examples part
embodiment 7 Chinese medicine composition of the present invention is on the impact of systemic lupus erythematosus (sle) MRL/lpr mice
1. experiment material
1.1 laboratory animals and grouping
8 week age, systemic lupus erythematosus (sle) (SLE) MRL/lpr mice 50, female, provided, after adaptability raises one week, be divided into 5 groups at random by body weight by Shanghai Slac Experimental Animal Co., Ltd., often organizes 10.ICR mice 10, female, as Normal group mice.
Normal group: gavage gives solvent;
SLE model group: gavage gives solvent;
Prednisone group: gavage gives the prednisone of 5mg/kg;
Chinese medicine composition low dose group: gavage gives medicine 0.5g/kg prepared by the embodiment of the present invention 1;
Dosage group in Chinese medicine composition: gavage gives medicine 1g/kg prepared by the embodiment of the present invention 1;
Chinese medicine composition high dose group: gavage gives medicine 4g/kg prepared by the embodiment of the present invention 1.
All test group administration every day 1 time, successive administration 3 weeks, gets blood for subsequent use, wins spleen at the end of administration.
1.2 reagent
(1) IL-10, anti-ds-DNA antibody test kit purchased from shanghai Ke Feng biological reagent company limited
(2) PBS: take following reagent 8.5gNaCl, 0.2gKCl, 2.85gNa 2hPO 412H 2o, 0.27gKH 2pO 4, with 1L distilled water standardize solution, above reagent is all be commercially available analytical pure
(3) erythrocyte cracked liquid: first prepare 0.83%NH 4cl, then prepare tris solution (take tris20.594g to be dissolved in 500-700ml distilled water, then adjust pH7.65 to 1L with 1MHCl), 0.83%NH 4cl and tris solution in 9:1 ratio mixing after and get final product.
(4) anti-mouse fluorescent-tagged mAbs CD3(FITC), be BeckmanCoulter Products
(5) anti-mouse fluorescent-tagged mAbs CD4(PE), CD8a(PE), Caltaglaboratories product
2. experimental technique
2.1 t lymphocyte subset cluster analysis
The preparation of Single-cell suspensions: the spleen of mice is put into the culture dish filling cold PBS liquid and cleans, 3mlPBS grinding is added in glass homogenizer, filter with 200 order stainless (steel) wires again, centrifugal for Splenic vessel liquid with rotating speed 1500rpm/min centrifugal 7 minutes, abandon supernatant, and add erythrocyte cracked liquid 2.5ml, mixing, leave standstill and after 2 minutes, add PBS liquid 2ml termination lytic response again, with 1500rpm/min centrifugal 7 minutes again, abandoning supernatant, adds PBS after washing three times, under fluorescence microscope, calculate cell number with PBS.Above operation all need on ice.
Use above Single-cell suspensions, after meter cell number, cell concentration is adjusted to 5 × 10 6cells/ml.Each group is got a wherein mouse boosting cell sample and is done subgroup analysis, and the mouse boosting cell sample of adjusted concentration is added flow cytometry dedicated pipe, and two pipes prepared by every mouse boosting cell sample, and often pipe adds sample 100 μ l.
5 μ lCD3(FITC are added at the first pipe containing sample dedicated pipe) and 3 μ lCD4(PE), the second pipe adds 5 μ lCD3(FITC) and 3 μ lCD8(PE).Room temperature black out hatches 20min, and each pipe adds 500 μ l sheath fluids, vibration mixing.Machine analysis in preparation.
2.2 serum IL-10, anti-ds-DNA antibody assay
Operate by test kit operating instruction.
The mensuration of 2.3 microdose urine proteins:
Experiment reagent: 10%(v/v) glacial acetic acid solution (PH2.8); 0.303mol/L glycine-glacial acetic acid buffer (PH3.0): take 22.72g glycine, be diluted to 1000ml with 10% glacial acetic acid solution, add NaN 3100mg, Room-temperature seal Absorbable organic halogens 1 year; Bromophenol blue (1.924mmol/L) stock solution: accurately take 257.36mgBPB, molten to 200ml with dehydrated alcohol, 4 DEG C of refrigerator Absorbable organic halogens 1 year; Bromophenol blue (0.231mmol/L) developer: get 60mlBPB stock solution, add 2.5mlTritonX-100, be diluted to 500ml with glycine-glacial acetic acid buffer, Room-temperature seal can preserve 1 year.
The collection of specimen and detection: in the 20th day mice is put in metabolic cage respectively and raises, collect 12 hours overnight urine, accurate recording urine volume.After sodium azide process, centrifugal (2000r/min) 10min, measures the mice urine 2ml of storage, respectively adds developer 1ml, and mixing (preventing bubble), measures absorbance A with ultraviolet spectrophotometer under 600nm.The content size of absorbance A reflection microdose urine protein, A value is less, and microdose urine protein content is lower.
Experimental data carries out statistical procedures in accordance with the following methods: adopt SPSS10.0 statistical software, and calculate data and represent with mean ± standard deviation (x ± s), many groups data compares employing variance analysis, compares and adopt t inspection in group.With p<0.05 for there being statistical significance.
experimental result
3.1 the present invention are on the impact of SLE T lymphocyte subsets in spleen of mice immunized
CD 3+cD 4+lymphocyte is helper T lymphocyte (Th), CD 3+cD 8+lymphocyte mainly plays inhibition regulating action, SLE mouse model group CD 3+cD 4+lymphocyte level than the decline of Normal group, SLE mouse model group CD 3+cD 8+lymphocyte level than the rising of Normal group, the CD that the present invention can make SLE mice decline 3+cD 4+t cell rises, and makes the CD of rising 3+cD 8+t declines, and wherein in Chinese medicine composition, dosage group effect is better, and this shows, medicine of the present invention can correct the imbalance state of SLE mouse T cell subgroup.Result of the test is in table 1.
Table 1 the present invention is on the impact of SLE T lymphocyte subsets in spleen of mice immunized
3.2 the present invention are on the impact of serum IL-10, anti-ds-DNA antibody content
Compare with Normal group, IL-10 and the anti-ds-DNA antibody level of SLE model mice obviously raise, compared with SLE model group, the present invention significantly can reduce SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition.This shows, medicine of the present invention is remarkable for SLE mice therapeutic effect.Result of the test is in table 2.
Table 2 the present invention is on the impact of SLE mice serum IL-10, anti-ds-DNA antibody content
*compared with Normal group, p<0.05; *compared with Normal group, p<0.01;
#compared with SLE model group, p<0.05; # #compared with SLE model group, p<0.01.
3.3 the present invention are on the impact of SLE mouse retention microalbumin content
Microalbuminuria reflection renal abnormality leaky protein, only occur minute quantity albumin in Normal group urine, SLE model group albumin content obviously raises, and reflection SLE mouse kidney has damage; Compared with model group, the present invention significantly can reduce albuminous content in SLE mice urine, and Chinese medicine composition low, middle dosage group effect is particularly remarkable, is better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference.This shows further, and medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.Result of the test is in table 3.
Table 3 the present invention on the impact of SLE mouse retention microalbumin content ( ± S)
*compared with Normal group, p<0.05; *compared with Normal group, p<0.01; #compared with SLE model group, p<0.05; # #compared with SLE model group, p<0.01.
In the test of t lymphocyte subset cluster analysis, compared with SLE model group, the CD that the present invention can make SLE sample mice decline 3+cD 4+t cell rises, and makes the CD of rising 3+cD 8+t declines, and corrects the imbalance state of T cell subgroup; In serum IL-10, the test of anti-ds-DNA antibody assay, compared with SLE model group, the present invention significantly can reduce the rising of SLE mice serum IL-10 and anti-ds-DNA antibody level, wherein dosage group and Normal group there was no significant difference in Chinese medicine composition, illustrates that medicine of the present invention is remarkable for SLE mice therapeutic effect; In the determination test of microdose urine protein, SLE model group albumin content obviously raises, reflection SLE mouse kidney has damage, the present invention significantly can reduce albuminous content in SLE mice urine, Chinese medicine composition low, middle dosage group effect is particularly remarkable, be better than positive drug, and low, the middle dosage group of Chinese medicine composition and Normal group there was no significant difference, show that medicine of the present invention has outstanding therapeutic effect for the damage of SLE mouse kidney.
embodiment 8 Chinese medicine composition of the present invention is to the improvement result of rat blood stasis models
Get healthy SD rat, body weight 180-200g, 70, male and female half and half, be divided into 7 groups at random by body weight: Normal group, model group, Tripterygium Hypoglaucum Hutch Tablet group, JINGTONGLING group and basic, normal, high group of Chinese medicine composition of the present invention (obtaining by Chinese medicine composition prescription described in embodiment 1 and preparation technology), often organize 10.Gastric infusion, successive administration 14 days, Normal group and model group are to 0.5%CMC, and all the other give the corresponding medicine described in medicine as follows:
Tripterygium Hypoglaucum Hutch Tablet group: gavage gives the Tripterygium Hypoglaucum Hutch Tablet of 2g/kg;
Chinese medicine composition low dose group: gavage gives medicine 0.5g/kg prepared by the embodiment of the present invention 1;
Dosage group in Chinese medicine composition: gavage gives medicine 1g/kg prepared by the embodiment of the present invention 1;
Chinese medicine composition high dose group: gavage gives medicine 4g/kg prepared by the embodiment of the present invention 1.
Successive administration is after the 13rd day, and except Normal group, all the other treated animals press 1mg/Kg subcutaneous injection adrenalin hydrochloride, 2 times/day, interval 4h, and after first time injection, animal is put into 15min in 4 DEG C of frozen water by 2h.Administration is got 4-5ml blood anticoagulant heparin on the 15th day and is measured blood rheology parameter, gets liver and to weigh conversion organ coefficient.
Result shows, and model group compares with normal control, the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity all have and significantly increase ( p<0.05).Compare with model group, Chinese medicine composition of the present invention each dosage group basic, normal, high all significantly or pole significantly reduce the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity, reduction amplitude amount effect relationship, wherein high dose there were significant differences ( p<0.05).Under same experiment condition, positive control drug Tripterygium Hypoglaucum Hutch Tablet group also reduces whole blood height cut index, the low cut index of whole blood, erythrocyte aggregation index, but its to the improvement effect of hemorheology index all not as good as Chinese medicine composition of the present invention.
table 4 chinese medicine composition of the present invention on the impact of rat blood stasis models lectin from hemolymph ( ± s)
Note: compare with normal control, # p< 0.05, ## p< 0.01;
Compare with model group, * p< 0.05, * p< 0.01.

Claims (5)

1. a systemic lupus erythematosus merges vasculitic Chinese medicine composition, it is characterized in that, it is made up of the raw material of following weight portion: Fructus Arctii 10-12 part, Herba Schizonepetae 5-8 part, Radix Astragali 6-9 part, Semen Cuscutae 3-5 part, Radix Rehmanniae 10-12 part, Herba Andrographis 10-12 part, Rhizoma Chuanxiong 3-5 part, Radix Tripterygii Wilfordii 3-5 part, Folium Ginkgo 10-12 part, Ramulus Cinnamomi 8-10 part, Herba Ecliptae 6-9 part, Radix Stellariae 10-12 part, Herba Scutellariae Barbatae 10-12 part, Radix Salviae Miltiorrhizae 10-12 part, Pollen Typhae 12-15 part, Radix Ophiopogonis 9-12 part.
2. Chinese medicine composition as claimed in claim 1, is characterized in that, described Chinese medicine composition is also containing Radix Angelicae Sinensis 5-8 part and Radix Notoginseng 12-15 part.
3. Chinese medicine composition as claimed in claim 1 or 2, is characterized in that described Chinese medicine composition is powder, water preparation, tablet or capsule.
4. Chinese medicine composition as claimed in claim 1 or 2, it is characterized in that the preparation method of described Chinese medicine composition comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40% ~ 95% is added according to 4 ~ 9 times of coarse powder gross weight, reflux, extract, three times, return time is 2 ~ 5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying; Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
5. the Chinese medicine composition described in claim 1 or 2 is preparing the purposes in systemic lupus erythematosus merging vasculitis medicine.
CN201410812739.2A 2014-12-24 2014-12-24 Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof Pending CN104547514A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410812739.2A CN104547514A (en) 2014-12-24 2014-12-24 Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410812739.2A CN104547514A (en) 2014-12-24 2014-12-24 Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof

Publications (1)

Publication Number Publication Date
CN104547514A true CN104547514A (en) 2015-04-29

Family

ID=53065285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410812739.2A Pending CN104547514A (en) 2014-12-24 2014-12-24 Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof

Country Status (1)

Country Link
CN (1) CN104547514A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104825690A (en) * 2015-05-30 2015-08-12 青岛辰达生物科技有限公司 Traditional Chinese medicine composition for treating lupus nephritis and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675986A (en) * 2008-09-18 2010-03-24 天津市中宝制药有限公司 Lupus III traditional Chinese medicine composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101675986A (en) * 2008-09-18 2010-03-24 天津市中宝制药有限公司 Lupus III traditional Chinese medicine composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
范永升等: "系统性红斑狼疮中医药研究新进展", 《浙江中医学院学报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104825690A (en) * 2015-05-30 2015-08-12 青岛辰达生物科技有限公司 Traditional Chinese medicine composition for treating lupus nephritis and application thereof

Similar Documents

Publication Publication Date Title
CN103705754B (en) A kind of Chinese medicine composition of systemic lupus erythematosus
CN101310751B (en) Detection method of medicine composition for replenishing qi and blood
CN103830577B (en) A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease
CN104127808B (en) Treat Chinese medicine preparation of malignant tumour and preparation method thereof
CN108143825B (en) Medicine for treating psoriasis, preparation method and detection method thereof
CN102657736B (en) Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition
CN104042895A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof
CN100518809C (en) Medicinal composition for curing diabetes and nephropathy and its preparing method
CN105079143A (en) Medicine composition for treating nephropathy
CN104547514A (en) Traditional Chinese medicine composition for treating systemic lupus erythematosus rheumatoid arthritis vasculitis and application thereof
CN102652774B (en) Drug composition for treating leukopenia and hypoimmunity caused by chemoradiotherapy and preparation method and quality detection method
CN104547674A (en) New application of traditional Chinese medicinal composition
CN100542597C (en) A kind of Chinese medicine preparation technology who treats vocal nodule, polyp of vocal cord symptom and uses thereof
CN105030562B (en) A kind of antiallergy complex polysaccharide composition and its preparation method and application
CN104288238B (en) A kind of medicine for the treatment of intestinal irritable syndrome and preparation method thereof and detection method
CN103948754B (en) Drug for treating renal-deficiency humid-heat type chronic nephritis
CN104825690A (en) Traditional Chinese medicine composition for treating lupus nephritis and application thereof
CN102188592A (en) Medicine for treating thrombocytopenia after tumor chemotherapy and preparation method thereof
CN100998687B (en) Medicine composition for treating chronic gastritis, and its preparing process
CN104940599A (en) Application of traditional Chinese medicine composition in preparation of medicines for improving lipid metabolism
CN104688723A (en) Application of anhydroicaritin in preparation of medicine for treating anaemia
CN101543574A (en) Chinese medicinal composition for treating pulmonary interstitial fibrosis
CN104042898B (en) Traditional Chinese medicine composition for treating fetomaternal blood group incompatibility and preparation method thereof
CN105663626A (en) Rhizoma anemarrhenae effective part as well as preparation method and application thereof
CN106177262A (en) One is used for treating the uremic Chinese medicine composition of nephropathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20150429